Synonym
BSJ-03-123 HCl; BSJ-03-123 hydrochloride, BSJ-03-123; BSJ03-123; BSJ 03-123; BSJ-03123; BSJ03123; BSJ 03123;
IUPAC/Chemical Name
N-(2-(2-(2-(2-(4-(6-((3-acetyl-1-cyclopentyl-4-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl)amino)pyridin-3-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide hydrochloride
InChi Key
YFXIGRICQUOWHV-UHFFFAOYSA-N
InChi Code
InChI=1S/C48H57N9O11.ClH/c1-30-35-28-51-40(26-37(35)56(32-6-3-4-7-32)47(63)43(30)31(2)58)52-39-12-10-33(27-50-39)55-17-15-54(16-18-55)19-21-66-23-25-67-24-22-65-20-14-49-42(60)29-68-38-9-5-8-34-44(38)48(64)57(46(34)62)36-11-13-41(59)53-45(36)61;/h5,8-10,12,26-28,32,36H,3-4,6-7,11,13-25,29H2,1-2H3,(H,49,60)(H,50,51,52)(H,53,59,61);1H
SMILES Code
O=C(NCCOCCOCCOCCN1CCN(C2=CC=C(NC3=CC4=C(C=N3)C(C)=C(C(C)=O)C(N4C5CCCC5)=O)N=C2)CC1)COC6=CC=CC(C(N7C(CC8)C(NC8=O)=O)=O)=C6C7=O.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
972.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Schmalzbauer BS, Thondanpallil T, Heller G, Schirripa A, Sperl CM, Mayer IM,
Knab VM, Nebenfuehr S, Zojer M, Mueller AC, Fontaine F, Klampfl T, Sexl V,
Kollmann K. CDK6 Degradation Is Counteracted by p16INK4A and
p18INK4C in AML. Cancers (Basel). 2022 Mar 18;14(6):1554. doi:
10.3390/cancers14061554. PMID: 35326705; PMCID: PMC8946512.
2: Ataei-Nazari S, Amoushahi M, Madsen JF, Jensen J, Heuck A, Mohammadi-
Sangcheshmeh A, Lykke-Hartmann K. Cyclin-dependent kinase 6 (CDK6) as a potent
regulator of the ovarian primordial-to-primary follicle transition. Front Cell
Dev Biol. 2022 Dec 23;10:1036917. doi: 10.3389/fcell.2022.1036917. PMID:
36619863; PMCID: PMC9816807.
3: Brand M, Jiang B, Bauer S, Donovan KA, Liang Y, Wang ES, Nowak RP, Yuan JC,
Zhang T, Kwiatkowski N, Müller AC, Fischer ES, Gray NS, Winter GE. Homolog-
Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. Cell
Chem Biol. 2019 Feb 21;26(2):300-306.e9. doi: 10.1016/j.chembiol.2018.11.006.
Epub 2018 Dec 27. PMID: 30595531; PMCID: PMC6444916.
